OBJECTIVE:To investigate clinical efficacy and safety of conjugeted estrogen tablets combined with Salmon calci-tonin acetate injection and Alendronate sodium tablets in the treatment of osteoporosis in postmenopausal. METHODS:148 post-menopausal women with osteoporosis were randomly divided into observation group(78 cases)and control group(70 cases). Con-trol group was given Salmon calcitonin acetate injection hypodermically or intramuscularly,100 IU each time,once a day in first week,every two days in second week,every three days in third week,21 times of consecutive injection as a treatment course;Alendronate sodium tablet,70 mg each time,once a week,3 months as a treatment course. Based on control group,observation group was additionally given conjugeted estrogen tablets,0.625 mg each time,qd,for consecutive 3 weeks,drug withdrawal for one week,and then continued to taking drug,for 3 months in total. Clinical efficacy of 2 groups were observed as well as BGP, bone metabolism index as human collagen type Ⅰ N-terminal peptide (NTX) and ALP,bone density and ADR before and after treatment. RESULTS:After treatment,total effective rate of observation group was 94.87%,which was significantly higher than 78.57% in control group,with statistical significance(P<0.05);BGP,lumbar spine and thigh-bone density of 2 groups were all improved significantly,and the improvement of observation group was more significant than that of control group,with statistical significance (P<0.05). NTX and ALP of 2 groups were decreased significantly,and the decrease of observation group was more significant than that of control group,with statistical significance (P<0.05). The incidence of ADR was 12.82% in observation group and 8.57% in control group,without statistical significance (P>0.05);various ADR disappeared after drug withdrawal. CONCLUSIONS:Conjugeted estrogen tablets combined with Salmon calcitonin acetate injection and Alendronate sodium tablets can effectively relieve bone pain,regulate bone metabolism,increase bone density and induce slight ADR in postmenopausal with osteoporosis.